Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-ASA and UDCA chemoprevention in ulcerative colitis
NL-OMON36920Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- Feb 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing Mesalazine + ursodeoxycholic acid, Mesalazine + UDCA placebo and Double placebo (3 arms). Primary endpoints: Change in aberrant crypt foci number and mRNA expression analysis of normal colonic mucosa. Started Feb 2010; status: active, not recruiting.
02
Drugs
Salcrozineursodeoxycholic acid
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on NL-OMON36920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36920.